Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Citius Pharmaceuticals Inc CTXR

Healthcare

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. It develops and commercializes critical care products with a focus on oncology, anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Its products include LYMPHIR, Mino-Lok, Halo-Lido, NoveCite and Mino-Wrap. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of... see more

Add To Watchlist

Recent & Breaking News (NDAQ:CTXR)

Citius Pharmaceuticals Issues May 2020 Shareholder Letter

PR Newswire May 12, 2020

Citius Announces Pre-IND Submission to FDA Under the Coronavirus Treatment Acceleration Program for a Novel Stem Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) in COVID-19

PR Newswire April 27, 2020

Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19

PR Newswire April 1, 2020

Citius Pharmaceuticals Announces Publication in Antimicrobial Agents and Chemotherapy Journal of Positive Preclinical Results for Mino-Lok® in Rapidly Eradicating Candida Auris

PR Newswire March 26, 2020

Citius Pharmaceuticals to Deliver Virtual Presentation at the Spring Investor Summit

PR Newswire March 18, 2020

Citius Pharmaceuticals, Inc. to Present at the Spring Investor Summit on March 25th-26th in New York City

Accesswire March 3, 2020

Citius Pharmaceuticals to Present at the 2020 LD Micro Virtual Conference

PR Newswire February 26, 2020

Citius Pharmaceuticals Cites Independent Estimates of Total Available World Market for Mino-Lok®

PR Newswire February 25, 2020

Citius Pharmaceuticals to Present at Noble Capital Markets' 16th Annual Investor Conference

PR Newswire February 10, 2020

Citius Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial

PR Newswire February 4, 2020

Citius Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

PR Newswire February 3, 2020

Biotech Companies Think Big with Specialization - Fighting Deadly Bacteria and Viruses

Newsfile January 27, 2020

Citius Announces Positive Outcome of Interim Futility Analysis for its Phase 3 Mino-Lok® Pivotal Trial

PR Newswire December 19, 2019

Citius Pharmaceuticals to Present at the 12th Annual LD Micro Main Event

PR Newswire December 4, 2019

Citius Pharmaceuticals Issues Corporate Update

PR Newswire November 8, 2019

Citius Pharmaceuticals to Present at the 5th Annual Dawson James Small Cap Growth Conference

PR Newswire October 24, 2019

Citius Pharmaceuticals to Present at the MicroCap Rodeo

PR Newswire October 15, 2019

Citius Reaches First Interim Analysis Milestone for Mino-Lok® Pivotal Trial

PR Newswire October 7, 2019

Citius Provides Update on Activities From IDWeek 2019

PR Newswire October 3, 2019

Citius Announces Closing of $7.0 Million Underwritten Offering Priced At-the-Market

PR Newswire September 27, 2019